Bio-Techne director Higgins exercises 15,940 options

Q: What did TECH director John L. Higgins report on September 28, 2026?

John L. Higgins exercised 15,940 options at $25.30 and acquired 15,940 common shares. He also had 5,562 shares delivered or withheld for payment of exercise price or tax liability, at $72.51 per share.

Higgins's holdings also list option awards with exercise prices from $31.26 to $128.81 and expirations through 2035.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

BIO-TECHNE Corp director John L. Higgins exercised 15,940 stock options on September 28, 2026, at an exercise price of $25.30, acquiring 15,940 common shares. He also had 5,562 shares delivered or withheld for payment of exercise price or tax liability, at $72.51 per share. Remaining option holdings include 12,500 options at $31.26, expiring October 26, 2027, and 3,777 options at $60.96, expiring October 30, 2035.

Insider Trade Summary

15,940 shares exercised/converted

Exercise 12 txns

Insider HIGGINS JOHN L

Role Director

Type	Security	Shares	Price	Value
Exercise	Stock Options (Right to Buy)	15,940	$0.00	$0.00
Exercise	Common Stock	15,940	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	5,562	$72.51	$403K
holding	Stock Options (Right to Buy)	--	--	--
holding	Stock Options (Right to Buy)	--	--	--
holding	Stock Options (Right to Buy)	--	--	--
holding	Stock Options (Right to Buy)	--	--	--
holding	Stock Options (Right to Buy)	--	--	--
holding	Stock Options (Right to Buy)	--	--	--
holding	Stock Options (Right to Buy)	--	--	--
holding	Stock Options (Right to Buy)	--	--	--
holding	Stock Options (Right to Buy) ^F1	--	--	--

Holdings After Transaction: Stock Options (Right to Buy) — 51,381 contracts (Direct); Common Stock — 77,254 shares (Direct)

Footnotes (1)

F1. The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.

Key Figures

Stock options exercised: 15,940 options Exercise price: $25.30 per share Common shares acquired: 15,940 shares +4 more

7 metrics

Stock options exercised 15,940 options September 28, 2026

Exercise price $25.30 per share Options exercised September 28, 2026

Common shares acquired 15,940 shares September 28, 2026

Shares delivered or withheld 5,562 shares For payment of exercise price or tax liability on September 28, 2026

Reported per-share price $72.51 per share 5,562 shares delivered or withheld

Underlying shares in option holding 12,500 shares Exercise price $31.26; expiration October 26, 2027

Underlying shares in option holding 3,777 shares Exercise price $60.96; expiration October 30, 2035

Key Terms

Stock Options (Right to Buy), exercise price, vesting

3 terms

Stock Options (Right to Buy) financial

"Stock Options (Right to Buy) for Common Stock"

exercise price financial

"exercise price of $25.30"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option vests on the earlier of"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did TECH director John L. Higgins report on September 28, 2026?

John L. Higgins exercised 15,940 options at $25.30 and acquired 15,940 common shares. He also had 5,562 shares delivered or withheld for payment of exercise price or tax liability, at $72.51 per share.

When do Higgins's 3,777 options vest?

The 3,777 options vest on the earlier of the one-year anniversary of the October 30, 2025 grant date or the date of Bio-Techne's 2026 annual meeting of shareholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/30/2026 - 04:13 PM Accepted by SEC EDGAR 09/30/2026 - 04:13 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HIGGINS JOHN L

(Last)

(First)

(Middle)

614 MCKINLEY PLACE NE

(Street)

MINNEAPOLIS

MINNESOTA

55413

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/28/2026		M		15,940	A	$0	82,816	D
Common Stock	09/28/2026		F		5,562	D	$72.51	77,254	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (Right to Buy)	$25.3	09/28/2026		M			15,940	10/26/2017	10/26/2026	Common Stock	15,940	$0	0	D
Stock Options (Right to Buy)	$31.26							10/25/2018	10/26/2027	Common Stock	12,500		12,500	D
Stock Options (Right to Buy)	$44.96							10/24/2019	10/25/2028	Common Stock	7,592		7,592	D
Stock Options (Right to Buy)	$50.41							10/24/2020	10/24/2029	Common Stock	8,044		8,044	D
Stock Options (Right to Buy)	$63.92							10/28/2021	10/29/2030	Common Stock	6,028		6,028	D
Stock Options (Right to Buy)	$128.81							10/27/2022	10/28/2031	Common Stock	2,532		2,532	D
Stock Options (Right to Buy)	$73.94							10/26/2023	10/27/2032	Common Stock	3,460		3,460	D
Stock Options (Right to Buy)	$61.51							10/24/2024	10/26/2033	Common Stock	3,937		3,937	D
Stock Options (Right to Buy)	$68.37							10/24/2025	10/24/2034	Common Stock	3,511		3,511	D
Stock Options (Right to Buy)	$60.96							⁽¹⁾	10/30/2035	Common Stock	3,777		3,777	D

Explanation of Responses:

1. The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.

	/s/ Andrew Nick as Attorney-in-Fact for John L. Higgins pursuant to Power of Attorney previously filed	09/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR